Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;35(11):2174-2187.
doi: 10.1080/14767058.2020.1774875. Epub 2020 Jun 7.

Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review

Alessandro Favilli  1 , Marta Mattei Gentili  2 , Francesca Raspa  2 , Irene Giardina  2 , Fabio Parazzini  3 , Amerigo Vitagliano  4 , Anna V Borisova  5 , Sandro Gerli  2
Affiliations
Review

Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review

Alessandro Favilli et al. J Matern Fetal Neonatal Med. 2022 Jun.

Abstract

Background: COVID-19 is a pandemic disease caused by the SARS-CoV-2 and it spread globally in the last few months. The complete lack of specific treatment forced clinicians to use old drugs, chosen for their efficacy against similar viruses or their in vitro activity. Trials on patients are ongoing but the majority of information comes from small case series and single center reports. We aimed to provide a literature review on the putative effectiveness and safety of available treatments for COVID-19 in pregnant women.

Methods: We reviewed all the available literature concerning the drugs that have been used in the treatment of COVID-19 during pregnancy and whose safe assumption during pregnancy had been demonstrated by clinical studies (i.e. including studies on other infectious diseases). Drugs contra-indicated during pregnancy or with unknown adverse effects were not included in our review.

Results and conclusions: Clinical trials are not often conducted among pregnant patients for safety reasons and this means that drugs that may be effective in general population cannot be used for pregnant women due to the lack of knowledge of side effects in this category of people .The choice to use a specific drug for COVID-19 in pregnancy should take into account benefits and possible adverse events in each single case. In the current situation of uncertainty and poor knowledge about the management of COVID-19 during pregnancy, this present overview may provide useful information for physicians with practical implications.

Keywords: COVID-19; SARS-CoV-2; pregnancy; therapy.

PubMed Disclaimer

References

    1. Poon LC, Yang H, Kapur A, et al. . Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. Int J Gynaecol Obstet. 2020;149(3):273–286. - PMC - PubMed
    1. Wong SF, Chow KM, Leung TN, et al. . Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191(1):292–297. - PMC - PubMed
    1. Siston AM, Rasmussen SA, Honein MA, et al. . Pandemic 2009 influenza A (H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303(15):1517–1525. - PMC - PubMed
    1. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: report of two cases & review of the literature. J Microbiol Immunol Infect. 2019;52(3):501–503. - PMC - PubMed
    1. Gisanddata [Internet]. Baltimore (MD): Johns Hopkins University; COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) [updated 2020 May 22]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594... [29907538]